pomaglumetad methionil

Pomaglumetad methionil is a small molecule, oral prodrug of the active compound LY404039, developed as a selective agonist for metabotropic glutamate receptor subtypes 2 and 3 (mGluR2 and mGluR3). It was designed to modulate glutamatergic activity by reducing presynaptic release of glutamate at synapses, with the aim of treating schizophrenia and other psychotic or anxiety disorders. Unlike traditional antipsychotics that target dopamine receptors, pomaglumetad methionil does not have appreciable affinity for biogenic amine receptors and is not associated with weight gain or metabolic side effects typical of many antipsychotics. The drug was originally developed by Eli Lilly but later licensed to Denovo Biopharma for further development in genetically defined subsets of schizophrenia patients[1][4][5].

Other names

pomaglumetad methionil monohydrate